The historical rank and industry rank for Reviva Pharmaceuticals Holdings's Price-to-Tangible-Book or its related term are showing as below:
RVPH'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.45 Med: 12.56 Max: 25.12
Current: 8.1
During the past 5 years, Reviva Pharmaceuticals Holdings's highest Price to Tangible Book Ratio was 25.12. The lowest was 1.45. And the median was 12.56.
RVPH's Price-to-Tangible-Book is ranked worse than 85.9% of 1220
companies
in the Biotechnology industry
Industry Median: 2.71
vs RVPH: 8.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Reviva Pharmaceuticals Holdings's Price-to-Tangible-Book
For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Reviva Pharmaceuticals Holdings's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Reviva Pharmaceuticals Holdings's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Reviva Pharmaceuticals Holdings Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RVPH has been successfully added to your 